Summary: Evaluated spironolactone versus placebo in patients with New York Heart Association (NYHA) functional class IV at some point, treated with ACE inhibitors and diuretics, and ejection fraction of < 35%. The primary endpoint of death from any cause was reduced. There was a reduction in sudden death and an improvement in symptoms across all subgroups.

Original Publication:

N Engl J Med. 1999 Sep 2;341(10):709-17.

Eponym: Randomized ALdactone Evaluation Study